

## Snapshot: Nuclear Receptors I

Cell

Neil J. McKenna and Bert W. O'Malley  
Baylor College of Medicine, Houston, TX 77030, USA

Receptor/Family*	Symbols	Ligands	Major Functions	Disease Associations	Target Genes
Estrogen receptors*	ER $\alpha$ /NR3A1; ER $\beta$ /NR3A2	Endogenous: 17 $\beta$ -estradiol	Regulation of cell growth and proliferation in multiple tissues (e.g., female reproductive tissues, bone, and CNS)	Cancer, cardiovascular, immune and inflammatory, metabolic, neurological, reproductive	$\uparrow$ MYC, NGF, BCL2, CXCL2, IGF1, TYMS; $\downarrow$ CD36, NDRG1, NCOR1, NCOA3
		Clinical: Mixed agonists (e.g. tamoxifen, raloxifene, and toremifene in breast cancer)			
		Xenobiotics: Bisphenol A, PCBs			
Androgen receptor	AR/NR3C4	Endogenous: Testosterone, dihydrotestosterone	Key role in male reproductive organs in addition to other systems (e.g., CNS)	Cancer, cardiovascular, immune, metabolic, neurological, reproductive	$\uparrow$ MYC, VEGF, BCL2, IGF1, MUC1, P66(Shc), CCND1; $\downarrow$ TSHA, TSHB, PTEN, FAS, CASP2, CTNND2, ESR2, TMPRSS2
		Clinical: Flutamide and bicalutamide for prostate cancer and alopecia			
Glucocorticoid receptor	GR/NR3C1	Endogenous: Cortisol (hydrocortisone)	Diverse developmental and physiological roles (e.g., antagonism of inflammatory signaling pathways, mediation of the stress response, and gluconeogenesis)	Metabolic, cardiovascular, immune and inflammatory, memory	$\uparrow$ SCNN1A, GADD45B, GILZ, TAT; $\downarrow$ BGLAP, POMC, INS
		Clinical: Fluticasone and prednisolone in inflammatory disorders			
Vitamin D receptor	VDR/NR1H1	Endogenous: Calcitriol (1',25' dihydroxy vitamin D3)	Maintenance of serum calcium and phosphate levels for skeletal integrity; antiproliferative in many tissues	Bone, cancer, cardiovascular, metabolic, immune and inflammatory, renal, neurological	$\uparrow$ FGF23, CYP24A1, CALB1, BGLAP, SPP1; $\downarrow$ IL2, PHEX
		Clinical: Paracalcitol for 2 $^{\circ}$ hyperparathyroidism in renal patients; Tacalcitol for psoriasis			
Thyroid hormone receptors*	TR $\alpha$ /NR1A1; TR $\beta$ /NR1A2	Endogenous: Thyroxine (T4), Triiodothyronine (T3)	Regulation of oxygen consumption; protein, carbohydrate, lipid, and vitamin metabolism	Thyroid conditions, cancer	$\uparrow$ ADRB1, PCK2, GH1, UCP1; $\downarrow$ DIO2, EHHADH, PRL, EGFR
		Clinical: Levo-thyroxine, triiodothyroacetic acid (TRIAc) in resistance to thyroid hormone			
Progesterone receptor	PR/NR3C3	Endogenous: Progesterone	Diverse reproductive functions (e.g., establishing and maintaining pregnancy, developing breast tissue, and stopping proliferation in the uterus)	Cancer, metabolic, reproductive	$\uparrow$ SERPINB14, FAS, MT2A, PGC, EGFR, IHH; $\downarrow$ ESR1, PGR, ANXA6
		Clinical: RU486 (Mifepristone) as an abortifacient			
Mineralocorticoid receptor	MR/NR3C2	Endogenous: Aldosterone	Regulating electrolyte and fluid balance in the kidney; specific roles in the CNS	Metabolic	$\uparrow$ SCNN1A, ATP1A1, ATP1B1, GILZ, SGK1, NDRG2
		Clinical: Spironolactone in hypertensive cardiovascular disease			
Peroxisome-proliferator-activated receptor- $\gamma$	PPAR $\gamma$ /NR1C3	Endogenous: FAs and FA intermediates	Regulation of adipocytes, insulin sensitivity and lipogenesis, and broader integration of energy, lipid, and carbohydrate metabolism	Cardiovascular, metabolic, cancer, neurological	$\uparrow$ FABP4, UCP1, AP2, PCK1, LPL, ADIPOQ, CD36, AQP7
		Dietary: FAs and PUFAs			
		Clinical: Thiazolidinediones (e.g., rosiglitazone) in type II diabetes			
Peroxisome-proliferator-activated receptor- $\alpha$	PPAR $\alpha$ /NR1C1	Endogenous: FAs and FA intermediates	Regulating energy expenditure; modulating fatty acid oxidation systems (mitochondria), peroxisome $\beta$ -oxidation, and microsomal $\omega$ -oxidation	Cardiovascular, metabolic, cancer, neurological	$\uparrow$ ACBP, ACOX1, APOA1, CPT1A, CYP11A1, CYP4A1, CYP7A1, SLC27A1, LCAS, MLYCD, SCD, FADS2, RETN, MYC, CCND1, IGFBP1, UCP1, KRT23, IL6, TF, PEX11A
		Clinical: Fibrates (e.g., fenofibrate) in hyperlipidemia			
		Dietary: FAs and PUFAs			
		Xenobiotics: DEHP, DEHA			
Peroxisome-proliferator-activated receptor- $\delta$ ( $\beta$ )	PPAR $\delta$ /NR1C2	Endogenous: FAs and FA intermediates	Regulating cell proliferation, differentiation, and migration in wound healing and inflammatory processes	Cardiovascular, metabolic, cancer, neurological	$\uparrow$ ACSL3, CPT1A, RGS3, RGS4, RGS5, ISG20, CXCL7, CCL21, RETN, CPT1A
		Dietary: FAs and PUFAs			
Retinoic acid receptors*	RAR $\alpha$ /NR1B1; RAR $\beta$ /NR1B2; RAR $\gamma$ /NR1B3	Endogenous: All- <i>trans</i> and 9- <i>cis</i> retinoic acid	Pleiotropic control of embryonic patterning and organogenesis, cell proliferation, differentiation, apoptosis and homeostatic control	Neurological and psychiatric, cancer	$\uparrow$ Numerous HOX genes, STRA6, HNF3A, CRABP2, ACADM, MECOM; $\downarrow$ CYP11A1, HOXB9
		Clinical: Tretinoin for treating acne and acute promyelocytic leukemia			
Liver X receptors*	LXR $\alpha$ /NR1H3; LXR $\beta$ /NR1H2	Endogenous: Oxysterols	Cholesterol and steroid sensors with roles in lipid and carbohydrate metabolism	Metabolic	$\uparrow$ SREBP1C, CYP7A1, ABC8, APOA1, APOE, LPL, PLTP
Retinoid X receptors*	RXR $\alpha$ /NR2B1; RXR $\beta$ /NR2B2; RXR $\gamma$ /NR2B3	Endogenous: 9- <i>cis</i> retinoic acid	Embryonic cell patterning and organogenesis, cell proliferation and differentiation, other functions as heterodimers with other nuclear receptors	Neurological and psychiatric, immune	$\uparrow$ many genes as heterodimers with other receptors (e.g., LXRs, PPARs, FXR, TRs, RARs; $\uparrow$ ABC1 (with LXR); $\downarrow$ CYP7A1 (with FXR)
Pregnane X receptor	PXR/NR1H2	Endogenous: Bile acids	Metabolism and transport of pharmaceutical drugs, xenobiotics, and toxic bile acids in the liver and GI tract	Immune	$\uparrow$ Multiple CYP2 and CYP3 gene family members, MDR1, MRP2, OATP2, UGT1A1, SULT, $\downarrow$ CYP7A1
		Xenobiotic: St. John's Wort (hyperforin), Taxol, rifampicin, phenobarbital			
		Dietary: Vitamin E, sulforaphane, Guggulipid			
Constitutive androstane receptor	CAR/NR1I3	Endogenous: Androstanol, androstenol	Metabolism of xenobiotics and endogenous lipids by regulating expression of cytochrome P450 genes	Involved in hepatotoxicity of acetaminophen	$\uparrow$ CYP2B10, CYP311A, CYP3A4, CYP1A2, CYP2B6 THRSF, SLC21A6, MRP2, MDR1, OATP2
		Xenobiotics: Phenobarbital, DEHP, Meclizine			
Farnesoid X receptor	FXR/NR1H4	Endogenous: Bile acids (e.g., chenodeoxycholic acid)	A sensor for bile acid that helps regulate bile acid homeostasis	Metabolic	$\uparrow$ SLC10A2, ABCB1, ABCB11, NROB2, HSD3B2, FETUB, ABCB4, FGF19, NOS2; $\downarrow$ CYP7A1, HNF1A, HNF4A, SLC01B1, SLC10A2
		Dietary: Cafestol, guggulsterone			

# SnapShot: Nuclear Receptors I

Cell

Neil J. McKenna and Bert W. O'Malley

Baylor College of Medicine, Houston, TX 77030, USA

Nuclear receptors (NRs) are a superfamily of transcription factors regulated by the direct binding of endogenous, dietary, clinical, and xenobiotic ligands. NRs are defined by the presence of conserved zinc finger DNA- and/or ligand-binding regions. NRs interact with a group of diverse factors named coregulators (i.e., coactivators and corepressors) to orchestrate programs of gene expression in specific tissues. Cell signaling pathways also can regulate NRs and their coregulators.

In this SnapShot, we present information on the endocrine nuclear receptors and the adopted orphan receptors. The endocrine receptors are activated by small and predominantly lipophilic ligands of the endocrine system, many of which have well known physiological roles. This subgroup consists of the first seven receptors in the chart: the estrogen (ER), androgen (AR), glucocorticoid (GR), vitamin D (VDR), thyroid (TR), progesterone (PR), and mineralocorticoid (MR) receptors. Adopted orphan receptors are a subgroup for which cognate ligands were uncharacterized at the time of their cDNA cloning but have since been identified. This group includes the last fourteen receptors in the chart: peroxisome-proliferator-activated (PPAR), retinoic acid (RAR), liver X (LXR), retinoic X (RXR), pregnane X(PXR), constitutive androstane (CAR), and farnesoid X (FXR) receptors. The ordering in the table is based on visits to the Nuclear Receptor Signaling Atlas (NURSA) Molecule Pages from May 2009 to May 2010.

The table includes information about NR ligands, target genes, functions, and disease associations. Although human gene names are shown (familiar name/Nuclear Receptor Nomenclature Committee name), regulation may have been demonstrated in human, mouse, or rat cells or tissues. In certain cases, subfamily members that are encoded by distinct genes are discussed collectively. However, each receptor has specific contributions to the endocrine signaling axis in question. Additional information, such as expression, knockout phenotypes, transcriptomics, cistromics, proteomics, and specific references for disease associations, is available at the NURSA Molecule Pages (<http://www.nursa.org>) and in the selected further reading provided below.

## Abbreviations

CNS, central nervous system; DEHA, Bis(2-ethylhexyl) adipate; DEHP, Bis(2-ethylhexyl) phthalate; GI, gastrointestinal; FAs, fatty acids; PCBs, polychlorinated biphenyls; PUFAs, polyunsaturated fatty acids.

## ACKNOWLEDGMENTS

The support of the NURSA Bioinformatics Resource in curating this information is gratefully acknowledged. N.J.M. and B.W.O. are supported by NIH U19-DK62434. The authors regret the omission of many important contributions to this field as a result of space constraints.

## REFERENCES

- Flamant, F., Baxter, J.D., Forrest, D., Refetoff, S., Samuels, H., Scanlan, T.S., Vennström, B., and Samarut, J. (2006). International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors. *Pharmacol. Rev.* 58, 705–711.
- Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., and Gustafsson, J.A. (2007). Estrogen receptors: how do they signal and what are their targets. *Physiol. Rev.* 87, 905–931.
- Mark, M., Ghyselinck, N.B., and Chambon, P. (2009). Function of retinoic acid receptors during embryonic development. *Nucl. Recept. Signal.* 7, e002.
- Moore, D.D., Kato, S., Xie, W., Mangelsdorf, D.J., Schmidt, D.R., Xiao, R., and Kliewer, S.A. (2006). International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnane X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. *Pharmacol. Rev.* 58, 742–759.
- Nuclear Receptors Nomenclature Committee. (1999). A unified nomenclature system for the nuclear receptor superfamily. *Cell* 97, 161–163.
- Pyper, S.R., Viswakarma, N., Yu, S., and Reddy, J.K. (2010). PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. *Nucl. Recept. Signal.* 8, e002.
- Scarpin, K.M., Graham, J.D., Mote, P.A., and Clarke, C.L. (2009). Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. *Nucl. Recept. Signal.* 7, e009.
- Sonoda, J., Pei, L., and Evans, R.M. (2008). Nuclear receptors: decoding metabolic disease. *FEBS Lett.* 582, 2–9.
- Tontonoz, P., and Spiegelman, B.M. (2008). Fat and beyond: the diverse biology of PPARgamma. *Annu. Rev. Biochem.* 77, 289–312.
- Zhou, C., Verma, S., and Blumberg, B. (2009). The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. *Nucl. Recept. Signal.* 7, e001.